The latest Q4 2012 sales figures for Zytiga of $264 M have been released today by Johnson & Johnson. The total sales for 2012 reached $ 961 M, just falling short of the billion dollar mark.
The 2012 sales figures for Zytiga are as follows:
Q1 $ 200 M
Q2 $ 232 M
Q3 $ 265 M
Q4 $ 264 M
Total $ 961 M
These figures show a levelling off of Zytiga sales with no significant growth over the last quarter. This may in part be due to the launch of Xtandi following its FDA approval in the post chemotherapy market. Xtandi is a competitor to Zytiga in the post chemotherapy space and some clinicians have opted to try this new treatment.
However Zytiga is now approved for the treatment of prostate cancer before chemotherapy and this is expected to double its market potential and 2013 sales may be as high as $ 2 billion.
No comments:
Post a Comment